Tokai Pharmaceuticals Inc. (TKAI) Stock Price & Overview
NASDAQ:TKAI
Current stock price
The current stock price of TKAI is 0.61 null. Today TKAI is down by -4.69%. In the past month the price decreased by -7.58%. In the past year, price decreased by -91.16%.
TKAI Key Statistics
- Market Cap
- 13.81M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.01
- Dividend Yield
- N/A
TKAI Stock Performance
TKAI Stock Chart
TKAI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TKAI. When comparing the yearly performance of all stocks, TKAI is a bad performer in the overall market: 96.45% of all stocks are doing better.
TKAI Earnings
TKAI Forecast & Estimates
TKAI Financial Highlights
Over the last trailing twelve months TKAI reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS increased by 59.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 100.27% | ||
| ROA | -87.37% | ||
| ROE | -101.88% | ||
| Debt/Equity | 0 |
TKAI Ownership
About TKAI
Company Profile
Tokai Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for prostate cancer and other hormonally-driven diseases. The Company's lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. Tokai Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Company Info
Tokai Pharmaceuticals Inc.
255 STATE STREET 6TH FLOOR
BOSTON MA 02109
CEO: Jodie P. Morrison
Phone: 617-225-4305
Tokai Pharmaceuticals Inc. / TKAI FAQ
What does Tokai Pharmaceuticals Inc. do?
Tokai Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for prostate cancer and other hormonally-driven diseases. The Company's lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. Tokai Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Can you provide the latest stock price for Tokai Pharmaceuticals Inc.?
The current stock price of TKAI is 0.61 null. The price decreased by -4.69% in the last trading session.
What is the dividend status of Tokai Pharmaceuticals Inc.?
TKAI does not pay a dividend.
What is the ChartMill rating of Tokai Pharmaceuticals Inc. stock?
TKAI has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.